Sign inJoin waitlistJoin the waitlist

Yago Nieto

Professor of Medicine · University of Texas M D Anderson Cancer Center

Credentials: · · · · ·

History

University of Texas M D Anderson Cancer Center
Present

University of Colorado School of Medicine
1996–1999
1994-1996 Fellowship in Medical Oncology
1994–1996
San Carlos University Hospital
1991–1993
Doctor of Medicine
1986–1990

Research

Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors
New England Journal of Medicine · 2020 · 1,804 citations
First- and second-line systemic treatment of acute graft-versus-host disease: recommendations of the American Society of Blood and Marrow Transplantation
Biology of Blood and Marrow Transplantation · 2012 · 500 citations
Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19+ B cell tumors: a phase 1/2 trial
Nature Medicine · 2024 · 428 citations

Elizabeth Shpall
171 papers
Richard Champlin
169 papers
Muzaffar Qazilbash
140 papers
Partow Kebriaei
125 papers
Chitra Hosing
124 papers
Uday Popat
119 papers
Qaiser Bashir
106 papers
Amin Alousi
77 papers
Samer Srour
75 papers · 2 as a fellow
Roy Jones
73 papers
BA
Borje Andersson
67 papers
Jeremy Ramdial
65 papers · 4 as a fellow

Grants

Prognostic Modeling of High-Risk Primary Breast Cancer
National Cancer Institute · R21
Contact PI · $303.7K · University of Colorado Denver
2002–2004

Clinical trials

Phase 2 Trial of CD70.CAR NK Cells for Patients With Primary Refractory or Early Relapsed Diffuse Large B-Cell Lymphoma and Hodgkin Lymphoma
Principal investigator · Not yet recruiting · Phase 2
M.D. Anderson Cancer Center
2026–2033
Phase1 Basket Trial Of CAR.70-Engineered IL15-Transduced With TGFBR2 Knock Out Cord Blood-Derived NK Cells For Relapsed/Refractory Lymphoid Malignancies
Principal investigator · Recruiting · Phase 1
M.D. Anderson Cancer Center
2026–2032
Trial of ONC-PluReceptor NK Cells With Epcoritamab and Tafasitamab for Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma
Principal investigator · Recruiting · Phase 1, Phase 2
M.D. Anderson Cancer Center
2026–2033
Vorinostat and Combination Chemotherapy Before Donor Stem Cell Transplantation for the Treatment of Relapsed Aggressive B-cell or T-cell Non-Hodgkin Lymphoma
Principal investigator · Withdrawn · Phase 2
M.D. Anderson Cancer Center
2021